Amgen Inc.
Amgen Reports Strong First Quarter 2025 Financial Results
Summary
Amgen Inc. reported strong financial results for the first quarter of 2025, with total revenues increasing by 9% to $8.1 billion compared to the same period in 2024. The company's GAAP earnings per share (EPS) were $3.20, and non-GAAP EPS increased by 24% to $4.90. Key drivers of the revenue growth were higher product sales, particularly from products like Repatha and EVENITY. Amgen also provided guidance for the full year 2025, expecting total revenues in the range of $34.3 billion to $35.7 billion and non-GAAP EPS between $20.00 and $21.20.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement